Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.Clinical Colorectal Cancer|July 10, 2023
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal CancerBeatrice Borelli, Veronica Conca, Martina Carullo, et al.JCO Precision Oncology|November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.European Journal of Cancer (Oxford, England : 1990)|August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 studyCarlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.British Journal of Cancer|June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2026
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatmentRoberto Moretto, Vittorio Studiale, Seung Won Hyun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerCarlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONODaniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.Pageof 4